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Abstract: During the last decade, the US Food and Drug Administration (FDA) have 
regulated a wide range of products, (foods, cosmetics, drugs, devices, veterinary, and 
tobacco) which may utilize micro and nanotechnology or contain nanomaterials. 
Nanotechnology allows scientists to create, explore, and manipulate materials in  
nano-regime. Such materials have chemical, physical, and biological properties that are 
quite different from their bulk counterparts. For pharmaceutical applications and in order to 
improve their administration (oral, pulmonary and dermal), the nanocarriers can be spread 
into microparticles. These supramolecular associations can also modulate the kinetic 
releases of drugs entrapped in the nanoparticles. Different strategies to produce these 
hybrid particles and to optimize the release kinetics of encapsulated drugs are discussed in 
this review. 
Keywords: pharmaceutical nanotechnologies; microparticles; microspheres; vectors; 
solubility; permeability; dosage form; administration routes; drug targeting; release; 
nanoemulsion; trojan 
 
1. Introduction 
Nowadays, nanotechnology is a multidisciplinary scientific field that is currently undergoing a large 
technological development. Nano-enhanced medicines are opening new doors for therapeutic delivery 
and targeting. These new technological advancements are finding new solutions for using efficiently 
(as for conventional formulations) a number of bioactive molecules having a poor bioavailability, 
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insolubility or drug instability. This results in an unprecedented multidisciplinary convergence of 
scientists dedicated to the study of a world so small. Nanotechnology is rapidly becoming an 
interdisciplinary field since biologists, chemists, physicists and engineers are all involved in the study 
of the properties of substances at the nanoscale regime. The main reason of interest in this field is 
because the nanoscale is the first point at which molecules can be assembled. 
Amongst the different industrial potentials, nanotechnology also has a high impact on the medical 
industry. With this kind of technology, patients can be administrated with fluids containing nanorobots 
or nanoprobes programmed to attack and reconstruct the molecular structure of cancer cells and 
viruses. There is even speculation that nanorobots could slow or reverse the aging process, and life 
expectancy could increase significantly. Nanorobots could also be programmed to perform delicate 
surgeries; such nanosurgeons could work at a level which can be a thousand times more precise than 
the sharpest scalpel [1]. 
Today, the main application of nanotechnology lies in the administration of nanoparticles (NPs) 
containing bioactive molecules as well as contrasting agent, for biomedical applications. NPs for 
nanomedicine are made from many different materials such as polymeric, inorganic, lipid, but all with 
the same purpose, which is the controlled delivery of drug or contrasting agent for diagnosis. In 
comparison with conventional formulations (e.g., macro-formulations like tablets, or micro-formulations 
like microspheres, microcapsules etc.), NPs present many advantages. The nanoscale allows better 
penetration of the colloids through biological tissues, through biological barriers and also through 
cellular membranes. It therefore follows that the efficiency in bringing the active molecules towards 
the administration sites is significantly increased; thus, for instance, improving drug absorption. The 
classical administration routes for the NPs are oral, pulmonary, dermal, rectal and injectable. However, 
still today, the main challenge of nanomedicines lies in the efficient administration of these NPs. The 
difficulty is the manipulation of NPs in order to bring them to the absorption sites, e.g., pulmonary 
alveoli, intestinal barriers, mucous membranes, etc. This is particularly true in the case of pulmonary 
administration. On the one hand, the size range of nanoparticles is too small to insure their retention in 
the deep lung: actually, NPs can be inhaled, but they are totally expelled during exhalation. Ideal 
particle sizes for the pulmonary alveoli administration are between 2 and 5 µm, corresponding to the 
typical size of microparticles. On the other hand, while the best systems for targeting the pulmonary 
alveoli are such microparticles, the latter are too big to diffuse and allow an efficient administration of 
the encapsulated drug as NPs can. The result is a real dilemma. Actually, a solution has been found by 
combining micro and nanoparticles, namely the encapsulation of nanoparticles in microparticles. The 
microparticles are brought onto the alveoli, and specifically release the NPs, which can diffuse through 
the barriers. Such multiscale nano-in-microparticles systems are called Trojan particles. Many 
different other potential applications of these Trojan systems are reported, and tailored in function for 
the administration routes, e.g., oral, dermal, intraocular. In the case of pulmonary, Trojan particles 
overcome an important technical challenge that is to bring and concentrate the NPs onto the specific 
absorption sites above-mentioned. In the present article, we propose a detailed review of the 
technologies inherent to the Trojan microparticles, by presenting in the first part, the technical details 
of their fabrication, processes and formulation methods, and, in the second part, by reviewing the 
potential of Trojan microparticles in terms of biopharmaceutical aspects and applications. 
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2. Fabrication, Physical Principles and Experimental Procedures 
In the context presented above, it is clear that this type of multiscale microsystem requires a 
multistep formulation procedure which involves two major steps. These steps are (a) fabrication of the 
nanoparticulate suspension, and (b) their integration with the microparticles. 
2.1. Nanoparticles 
In the present review, we will only discuss nanoparticles as an entity to be encapsulated for the 
fabrication of the Trojan particles, rather going through their synthesis aspect. The encapsulation of 
drugs into nanoparticles has been widely reported in literature [2–6]. Nanoparticles are generally 
defined as rigid colloidal particles having sizes from 1 nm to 1 μm. They are fabricated from 
macromolecular and/or molecular assemblies, polymers or lipids, in which the active principle is either 
dissolved, entrapped, encapsulated, adsorbed or attached to the external interface. The main advantage 
of nanoparticles as compared to other colloidal drug delivery systems (liposomes, niosomes, etc.) lies 
in their unique structural properties and stability. This point is of fundamental interest in order to 
maintain their size and morphology when they undergo the microencapsulation processes during the 
fabrication of Trojan microparticles. Nanoparticles are generally divided into two main families: 
nanospheres (which exhibit a homogeneous matricial structure) and nanocapsules (which have typical 
core-shell type morphology). The formulation processes as well as the nanoparticle structure are 
tailored according to the requirements in terms of drug encapsulation and drug delivery (biocompatibility 
of the polymer, physicochemical properties and solubility of the drug, therapeutic goals). 
The unique features of nanoparticles depend on their shape and size, chemical nature and/or surface 
functionalization allowing their diffusion into the tissues or organs at the administration site. NPs 
penetrate the cell membranes and are able to enter the cells located in these tissues [7]. Due to this, the 
delivery of bioactive molecule is not only enhanced in efficiency, but also such nanocarrier-based 
technologies allows the protection of the fragile encapsulated molecules, or they may protect living 
tissues from cytotoxic molecules, until they reach their target [6]. To summarize, the two fundamental 
points inherent to the nanoparticulate systems are (i) their nanometric size, and (ii) the encapsulation  
of active pharmaceutical ingredient (API). These two points should be taken into account, and 
thoroughly controlled when the microencapsulation of nanoparticles is designed for the fabrication of 
Trojan particles. 
Accordingly, the microencapsulation processes should, neither destroy the nanoparticle morphology, 
nor induce premature drug release (during processing) [8]. Besides, the Trojan fabrication processes 
have to be designed according to the chemical nature and physico-chemical properties of the 
nanoparticles suspension. These processes are discussed below; in the literature the most adopted 
technique to design such particles is the spray-drying process, which is quite compatible with such 
specifications. 
Another essential point related to the therapeutic goals and bioactive delivery lies in the API 
leakage over time, which is linked with nanoparticles’ loading capabilities, and their release profiles. 
Actually, one interesting point of the Trojan particles is the modification of the release profiles, which 
reduces the burst effect and slows the kinetics [8], finally resulting in improving and optimization of 
the API delivery. 
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2.2. Microparticles 
The second experimental challenge lies in the formulation of microparticles with the constraints 
presented above. The spray drying process with few modifications is most often used for the 
fabrication of Trojan particles (detailed below). Some modified spray drying methods using supercritical 
CO2 as antisolvent medium are also reported and are particularly efficient for the formulation of 
Trojan particles (e.g., in [9,10]). 
A spray dryer apparatus is generally used to transform liquid substances into powder materials quite 
rapidly and efficiently. This drying process is performed by atomization, which involves a very short 
drying time, thus enabling the drying of temperature-sensitive materials without degradation [11,12]. 
The spray drying process is largely used to improve product conservation in dried solid form. 
Moreover, as illustrated in the current review, with the development of technologies for encapsulating 
active compounds, emulsions, nanoparticles (or nanostructured materials), used in pharmaceutics, 
cosmetics and functional food preparation, this method has also been largely studied and used for 
encapsulation purposes. The powder generated is generally in the form of heterogeneous and amorphous 
microparticles, which can exhibit various structures, for example matricial (i.e., microspheres [13]) or 
hollowed morphologies. Particle structure, size and morphology, depends on various parameters, from 
physicochemical properties of the materials to the thermodynamic parameters and phenomena related 
to the two-phase flow in spray dryers. 
Actually, owing to the complexity of the phenomena involved, and due to a large number of 
processing and formulation variables, the physical description of the process and its effects on the 
resulting particles size and morphology is not well understood [11]. To summarize, the structural and 
morphological properties of the microparticles formed by spray-drying is a function of the feed 
solution concentration [14] as well as the solubility of the excipients [15–17]. Likewise, other physico-
chemical aspects, like precipitation kinetics and crystallization have also shown significant impact on 
(and/or can be affected by) the evaporation rate [18,19] and the drying temperature, which have a 
direct effect on the resulting particle morphology [20,21]. 
On the other hand, Tsapis et al. [22] emphasized the importance of another parameter, the Peclet 
number (Pe), in understanding the formation process, morphology and density of the particles. The 
Peclet number is a dimensionless mass transport number that characterizes the relative importance of 
diffusion and convection [23]. Pe actually gives an idea as to whether the microparticle structure will 
be a matricial, or rather hollow like “empty microcapsule”. This number is given by the ratio between 
two characteristic “times” which are critical for the drying process: the first one, τd, is the time spent 
by droplet in drying, and the second one, R2/D, corresponds to the time of diffusion of a solute 
(molecule or nanoparticles), to move from the external interface to the center of droplet (where R is the 
droplet radius, and D the diffusion coefficient of the solute or nanoparticle). 
ܲ݁ ൌ ܴ
ଶ
߬ௗܦ (1)
Pe appears to be closely linked to the processing parameters as well as to the chemical nature and 
mobility of the solutes. As a non-exhaustive list, this Pe is also influenced by the drying parameters 
like inlet temperature, pressure, gas flux (playing on τd), as well as by the pressure of the spraying gas, 
viscosity, chemical nature of the solute, intermolecular interactions, concentration of the solute, factors 
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related to the diffusion coefficients and to the droplet radius etc. On the other hand, Taspis et al. [24] 
and Marty and Tsapis [25] showed that the morphology of the particles could also depend on the 
mechanical properties of the material forming the wall, as well as on the colloidal interactions. This is 
studied through a parameter called buckling threshold, which is the time for which the surface of the 
droplets suddenly buckle like elastic shells. However, we chose here to focus the discussion below 
around the Peclet number, which allows describing and understanding, under a clear point of view, the 
relationship between the nature of the materials, drying process, and particle morphologies. 
Figure 1 presents SEM micrographs of microparticles spray dried in different conditions and 
materials. These illustrations show the influence of such macroscopic parameters on the Peclet 
number. Figure 1 (a,b) present microparticles made from the solution of gum Arabic at 10wt% in water, 
but spray dried with different apparatus, like the Büchi Mini Spray Drier B-290 [26] and the Büchi 
Nano Spray Drier B-90 [27], respectively. The spray drying technologies in both the cases are 
significantly different from each other, and as a result, particles of different size range are obtained. The 
particle size distribution for both the cases are shown in Figure 1, for Figure 1(a): (2.17 ± 0.66) μm [26] 
and for Figure 1(b): (0.55 ± 0.27) μm [27]. Similarly, the shape of the particles is also influenced, 
appearing as “deflated balls” in the first case, and more spherical in the second case: this means that Pe 
is different in both of these cases, and it is higher with the B-290 apparatus. So far as the spray dried 
solutions are strictly the same, this is an example of the influence of the droplet radius R on Pe (see 
Equation 1). It is however to be noted that the decrease of R can also result in the decrease in the value 
of ߬d (which goes to increase Pe), as was observed in Figure 1(b) where these two phenomena resulted 
in reduction of Peclet number. 
Figure 1(c), corresponds to 15 wt% of PVA aqueous solution spray dried with the Büchi Mini Spray 
Drier B-290. Here the particles morphologies corresponded to a Pe value lower than the one observed 
for gum Arabic in Figure 1(a) (in similar experimental conditions). This can be explained by the 
decrease of the mean particle size, measured as (1.39 ± 0.53) μm for PVA, which was due to the 
decrease of the surface tension at the air/water interface. Measurements of the average air/water surface 
tension during the first 30 seconds after the formation of drop (short times mimicking the conditions 
during the spray drying process), revealed that the values for gum Arabic and PVA are significantly 
different from each other ߛ௔௜௥/௪௔௧௘௥௚.஺. ൌ (71.35 ± 0.01) mN·m−1 and ߛ௔௜௥/௪௔௧௘௥௉௏஺ ൌ (42.67 ± 0.10) mN·m−1. 
This result also explains the presence of “wire-like” objects formed during the droplet formation, 
which was due to an interfacial phenomenon. Here the surface tension measurements were performed 
using a drop tensiometer (Teclis, Longessaigne, France). 
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Figure 1. SEM pictures of microparticles of different materials and/or spray dried under 
different conditions. All powders, excepted the one shown in (b), are spray dried with the 
Büchi Mini Spray Drier B-290, in exactly the same operational conditions (inlet 
temperature: 150 °C, solution feed rate: 10 mL·min−1, aspiration rate: 100%), whereas 
sample (b) was obtained using a different apparatus, the Büchi Nano Spray Drier B-90 
(with inlet temperature fixed at 100 °C feed rates at 10 mL·h−1, the drying gas flow rate 
equal to 100 L·min−1, and the spray mesh used in this study was the membrane with 4.0 μm 
sized holes). (a) Gum Arabic at 10 wt.% in water (B-290). (b) Gum Arabic at 10 wt.% in 
water (B-90). (c) Polyvinyl Alcohol at 15 wt.% in water. (d1) and (d2) Hydroxypropyl  
β-cyclodextrins (Kleptose® HPB from Roquette, France) at 15 wt.% in water; arrows 
highlight particular structures due to high Pe discussed in the text. (e) Hydroxypropyl  
β-cyclodextrins (Kleptose® HPB) at 15 wt.% in water, encapsulating oil-in-water  
nano-emulsions (dh = 85 nm) at a weight ratio of 1:4 (emulsion:polymer). 
 
Another example is the spray-drying of hydroxypropyl β-cyclodextrins in Figure 1(d1) and (d2), 
performed at similar operating conditions as in Figure 1(a) and (c). The micrograph clearly shows that 
critical structures were formed due to very high Peclet numbers, indicated by the white arrows on the 
figures, hollow structures with a thin polymer shell, either opened (arrows) or closed (deflated  
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ball-like) could be clearly seen in these microparticles. Compared to gum arabic as in (a) or PVA in 
(c), particles seem even more porous suggesting that the Pe number might be larger. Now, when a 
suspension of oily nano-droplets were added to the solutions spray dried in (d), the microparticle 
morphology as well as size changed drastically, presented in Figure 1(e). The particles appeared more 
spherical, probably correlated to a modification of the elastic properties of the particles. The size 
measured was (1.73 ± 0.56) μm (roughly similar to (d)), which could be due to the increase in ߬d since 
the concentration of solutes in the droplets was consequently increased. 
Figure 2. SEM pictures of (a) a typical hollow microparticle obtained by spray drying a 
solution of polystyrene nanoparticles (170 nm), and (b) magnified view of the particle 
surface in (a). Reproduced with permission from National Academy of Sciences,  
USA [22].  
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To summarize, we have seen that many different factors (operating parameters, formulation variables, 
nature of chemical) can have a significant impact on the Peclet number and particles morphologies. 
Accordingly, the molecular weight of solutes also have a significant impact on D and thus on the 
increase of Pe. Numerous examples are reported in literature with different morphologies, like 
hollowed, wrinkled, or dimpled particles (as also shown in Figure 1) for spray dried proteins [19,28–33], 
peptides [34,35], or polymers particles [17,36–41]. In this context, the spray drying of droplets 
containing nanoparticles can be considered as an extreme case when, compared to single molecules or 
macromolecules, or to the droplet surface, NPs can also be considered as immobile during the drying 
process. Accordingly, the diffusion coefficient is lowered and the Pe value is increased. The literature 
reports some examples of solutions composed of nanoparticles which are spray dried, this is reported 
in Figure 2 [22]. The results show hollow or “large porous” microparticles in which the cohesion 
between the NPs is due to weak forces between the interparticles. However, even if the nanoparticles 
induce an extreme reduction in D, the Peclet number does not become too high, as seen in Figure 1(e) 
in which a suspension of nano-emulsion mixed with a polymeric wall material (WM) was spray dried, 
details of which are given in [26,27]. The decrease of the diffusion coefficient D is counterbalanced by 
a decrease of the size and/or ߬d, or even could be simply inhibited by the presence of polymers serving 
as wall materials. There are various examples in the literature describing the formulation of Trojan 
particles, which can either be formulated with high Peclet number (hollowed, wrinkled, or dimpled, 
e.g., as illustrated in Figure 2) or with a spherical morphology (as presented in Figure 1(e)). These 
results not only depend on the operating parameters discussed above, but also on the presence, 
concentration, and mechanical properties of wall materials (e.g., polymers) solubilized in the spray 
dried solutions. Figure 3 corresponds to SEM micrographs of Trojan microparticles obtained via 
different experimental approaches. The three first examples presented in Figure 3(a–c), respectively 
reproduced from [7,42,43], show multiscale assembly with polymeric nanoparticles spray dried in an 
aqueous media. All these examples produced high-Pe microparticles morphologies, with a shell 
thickness as a function of the wall material content. In Figure 3(a), poly(D,L-lactide-co-glycolide) 
(PLGA) nanoparticles were mixed with an aqueous solution of hyaluronic acid (HA) which were then 
spray dried. The authors observed a clear relationship between increase in Pe value with a decrease in 
WM-to-nanoparticle weight ratio (i.e., an increase of the relative wall material content). This factor 
was fixed to 2:1 in Figure 3(a). The following micrograph, Figure 3(b), is of a similar system like that 
presented in Figure 2. This micrograph is of a dried suspension of NPs (without using any wall 
material). 
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Figure 3. SEM pictures of a representative panel of Trojan microparticles reported in 
literature. (a) Reproduced with permission from Elsevier [7]: spray dried (Büchi B-191) 
microparticles prepared with DPPC, HA and PLGA nanoparticles; Inset: Close-up on Trojan 
particle surface: one can distinguish nanoparticles. (b) Reproduced with permission from 
Elsevier [42]: spray dried (Büchi B-290) microparticles prepared with DPPC and  
PMMA-MeOPEGMa nanoparticles. (c) Reproduced with permission from Elsevier [43]: 
spray dried (Büchi B-290) microparticles prepared with mannitol and chitosan/TPP 
nanoparticles. (d) Reproduced with permission from Elsevier [44]: spray dried (Büchi  
B-191) microparticles prepared with colloidal silicon dioxide as drying auxiliary and  
oily-core PCL nanocapsules. (e) Reproduced with permission from Elsevier [10]:  
spray-dried microparticles of PLLA in organic solvent (dichloromethane) in supercritical 
CO2, encapsulating puerarin nanoparticles also generated through this supercritical CO2 
micronization process; Inset: Close-up on the puerarin NP after micronization.  
(f) Reproduced with permission from Elsevier [8]: PLGA microshperes obtained by a 
nonaqueous s/o/o/o [45,46] solid dispersion technique, encapsulating dexamethasone 
phosphate prepared with a supercritical CO2 nanoprecipitation process. 
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As expected, few microparticles formed with the assembled nanoparticles (poly-methyl 
methacrylatemethoxy(polyethylene glycol)methacrylate (PMMA-MeOPEGMa) polymer nanoparticle) 
were hollow with very thin shell (even reaching a thickness about one nanoparticle), however these are 
extreme cases with high Pe. In the case where small molecular weight wall materials were used (as 
illustrated in Figure 3(c) with mannitol) for encapsulating chitosan/tripolyphosphate (TPP) 
nanoparticles (also where WM-to-nanoparticle weight ratio is fixed at 9:1), the diffusion coefficient of 
the solutes (WM and NPs) was found to be increased, resulting in decrease of Pe value. This resulted 
in spherical shapes, however bigger particles still appeared to be hollow, with a shell thickness of 
about 4–5 μm. Replacing WM by inorganic nanoparticles, resulted in highly geometric microparticle 
morphologies. One example is given in Figure 3(d), where spherical microparticles encapsulating oily-
core poly(epsilon-caprolactone) nanocapsules (themselves encapsulating medium chain triglycerides), 
were spray dried using colloidal silicon dioxide as drying auxiliary. In contrary to the above examples, 
the particle morphology appeared quite homogeneous, spherical and seems to correspond to low values 
of Pe. This particular technology is described in detail in [47], where homogeneous particles with 
regular structures were obtained. The example shown in Figure 3(e) presents Trojan particles made by 
using the spray-drying technology in supercritical CO2 (as discussed above). The NPs obtained were 
dispersed in another organic phase (dichloromethane) containing a polymer (PLLA), and this mixture 
was once again spray-dried in CO2 in supercritical conditions. The last example of Figure 3(f) shows 
PLGA microspheres encapsulating drug nanoparticles, fabricated by the precipitation of PLGA by a 
specific mixing between polymer solvent and antisolvent. 
Comparing the different experimental techniques reported here, the Trojan particles fabricated 
exhibit very similar size distributions, between one and ten micrometers. In view of the literature 
reviewed here, it seems that the size distribution of the Trojan microparticles generated are dependent 
on several factors, like the relative proportion between wall materials and NPs, the chemical nature of 
the materials used, the surface active properties of the NPs [26], and the apparatus used. In this way, 
we have recently reported [27] the possibility to generated submicronic Trojan particles encapsulating 
nano-emulsions by using the Büchi Nano Spray Drier B-90. This is illustrated in Figure 4 which 
presents Trojan particles encapsulating nano-emulsions using different wall materials like gum Arabic 
and whey protein, by using spray-drying apparatus: Büchi Mini Spray Drier B-290 and Büchi Nano 
Spray Drier B-90. In all these examples, exactly the same nano-emulsion was encapsulated in the 
different WM or using different spray drier apparatus. As discussed above with Figure 1, the drying 
technique strongly influences the Pe value as well as the size distribution of the particles, and it can be 
clearly seen that this behavior remains true even in the presence of nanoparticulate systems like lipid 
nanodroplets. Figure 4(a,b) presents the same nano-emulsion plus gum Arabic at identical 
concentrations, spray dried with the Büchi B-290 and B-90. The results clearly illustrate their influence 
in terms of size and Peclet number. The nature of the wall materials is also an important factor, which 
affects the microparticles’ morphology as illustrated, for instance with whey protein in Figure 4(c) 
compared to gum Arabic in Figure 4(a). 
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Figure 4. Trojan microparticles encapsulating nano-emulsions. (a) Wall materials: gum 
Arabic, Spray drier: Büchi Mini Spray Drier B-290. (b) Wall materials: gum Arabic, Spray 
drier: Büchi Nano Spray Drier B-90. (c) Wall materials: whey protein, Spray drier: Büchi 
Mini Spray Drier B-290. ((a) and (c) from [26], and (b) Reproduced with permission from 
Elsevier [27]). 
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2.3. Impact on the Drug Delivery and Release Kinetics 
Figure 5. (a) Reproduced with permission from Elsevier [8]: (a1) in vitro release profile of 
dexamethasone phosphate from polylactidecoglycolide microencapsulated drug 
microparticles, and (a2) in vitro release profile of dexamethasone phosphate from Trojan 
microparticles: polyactide-co-glycolide microencapsulated drug nanoparticles.  
(b) Reproduced with permission from Elsevier [7]: in vitro release profiles of 
dexamethasone from nanoparticles (NPs) and from Trojan particles in HEPES buffer under 
sink conditions. 
 
Although Trojan particles offer new possibilities for increasing the drug loading as well as its 
diffusion through living tissues, another important point lies in the drug release kinetics which can be 
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modified using this technology. Most of the reports dealing with Trojan particles for drug delivery 
open a new possibility of a decrease in the burst release of the drug, and even in reduction of the 
release kinetics. Details of these can be found, in [7,8], illustrated in Figure 5(a,b), respectively. The 
first one (a), corresponds to Trojan microparticles as shown above in the SEM micrograph in  
Figure 3(f) made up of drug (dexamethasone) nanoparticles encapsulated in PLGA microparticles.  
Figure 5(a1) shows the drug release profile when the drug is encapsulated in microparticles, while 
Figure 5(a2) corresponds to Trojan particles. Here it can be seen that not only the burst effect was 
inhibited, but the drug release kinetics was also reduced. In this example, the resulting release profile 
was close to a zero-order process, which was likely governed by the polymer erosion. In other cases, 
like that presented in Figure 5(b), the drug was first encapsulated in polymeric nanoparticles (PLGA), 
followed by encapsulation in another polymeric matrix (hyaluronic acid). Here also, the burst effect 
was reduced with the Trojan system (open squares) compared to the drug release from the 
nanoparticles (filled triangles). However, the shapes of the two curves remained comparable i.e., they 
could be driven by the drug diffusion at non-constant activity. This latter behavior is widely reported 
in literature and simply depends on the physicochemical properties of the Trojan system, like chemical 
nature of polymers and drug [42,48–50]. Actually, this phenomenon is still unexplained and there is no 
hypothesis to explain such a phenomenon. Moreover, establishing a general rule for the drug release 
from Trojan particles is not possible, as (i) all the Trojan particles are potentially different, the drug 
encapsulated can show different physicochemical properties, and (ii) the processing (e.g., spray drying 
conditions) as well as the formulation (e.g., drug concentration) parameters can play a significant role in 
the kinetics profiles. Overall, the drug leakage from Trojan particles is a result of combination of many 
factors like the drug release from the nanoparticles and microparticles matrix, along with the 
nanoparticles leakage from the Trojan matrix. 
3. Biopharmaceutical Applications 
In order to optimize the pharmacological activity and the therapeutic action, each drug has to be 
formulated in a particular dosage form with excipients improving the therapeutic effectiveness of the 
drug. Indeed, the therapeutic action of extra-vascular (pulmonary, oral, dermal, nasal and rectal) 
administrations is related to drug bioavailability. This is a quantitative and kinetics concept measuring 
the rate and the amount of a drug to penetrate the different membrane barriers allowing it to reach the 
target (organs, tissues, receptors). Therefore, the final goal of a biopharmaceutical development is to 
design a dosage form which can allow drug release “on demand” and to be able to reach specific 
targets. This approach also contributes to improve the socio-economic and industrial aspects. The 
biopharmaceutical developments of accelerated, sustained or prolonged drug release from a dosage 
form can illustrate this approach. Indeed, in this case, these new medicines can optimize the therapeutic 
effect of the drug and in some cases lead to a second pharmacological application of an already  
well-known drug. The ideal drug candidates for a biopharmaceutical development comprise drugs with 
poor solubility, permeability and stability when there are administered by another route rather than the 
intravascular one. As an example, one can mention (i) polypeptide antibiotics (capreomycin, teicoplanin, 
vancomycin, conjugated ampicillin) which are very active towards Gram-positive and Gram-negative 
microorganisms, and allow loco-regional or site-specific delivery; (ii) paclitaxel, 5-fluorouracil, 
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tamoxifen or antitumor agents of natural origin for oral therapy in order to improve the bioavailability 
or to favor a lymphatic uptake; (iii) nucleic acids, guanosine derivatives, adenosine derivatives 
(ciclopentiladenosine) or in combination with dopamine for nasal delivery in order to target the brain 
or antigenic peptides in order to induce an immune response. 
To overcome these problems, some strategies consist of modifying the chemical structures  
of the active compounds. Obviously, the chemical modifications will change the physicochemical 
characteristics of the drugs and will generate new chemical entities. 
More recently, alternative strategies have been suggested which consist of development of new 
products rather than chemical modification of the molecule. Pharmaceutical technology, for example, 
uses particular excipients that can mask the chemical structure, allowing the drug to pass unmodified 
for biological availability. Thus, pharmaceutical technology does not generate new drugs but new dosage 
forms. The development of an already known active compound formulated in an innovative dosage 
form makes available a new product at lower costs, revaluating active compounds well established in 
clinical practice. Technology indeed is able to optimize the biological availability of drugs. 
To reach these aims, new raw materials, new dosage forms and technologies are required. From a 
biopharmaceutical point of view, the ideal size of the basic particle has to be in nanometric scale  
(as described above) but from a pharmaceutical technology point of view, the handling (flow, 
electrostatic problems...) of bigger particles is easier. Indeed, particles having a very small size i.e.,  
in the nanoscale, show difficulty in free flow and are prone to electrostatic charges on the surfaces. For 
these reasons, and easy handling the ideal size of the particles has to be in a micrometric range. To 
satisfy the biopharmaceutical and technological requirements, the best compromise consists of 
building hybrid micrometric particles which can encapsulate particles of nanometric range. 
Hybrid carriers having nano/micro dimensions, also named as Trojan microparticles, have been 
studied and developed as new drug products capable of carrying and release of active substances with 
unfavorable biopharmaceutical properties. Indeed, the use of particulate systems can affect their 
biological availability and is capable of improving drug bioavailability. These particulate vectors can 
be incorporated into classical dosage forms for different administration routes. 
The main goal of these pharmaceutical nano/microtechnologies is based on the discovery of new 
particulate carriers for drugs exhibiting critical biopharmaceutical or kinetics properties. The use of 
new raw materials or their combinations coupled to innovative physical structures and new 
manufacturing procedures allow reaching this aim. Therefore, the Trojan microparticles technologies 
are focused on the preparation of hybrid particles containing drugs having low solubility, poor 
permeability and short stability by means of new materials, mechanisms, structures, technologies and 
manufacturing procedures. These new strategies for the formulation of drugs have lead to the alteration 
of pharmacokinetics/pharmacodynamics of active substances by modifying their absorption and 
distribution by means of rate and site controlled delivery. 
From a biopharmaceutical point of view, several advantages can be attributed to these particulate 
technologies, like: (i) reduction of the dose administered, (ii) increasing the bioavailability of poorly 
soluble and absorbed drugs, (iii) prolonged action of the drug after one administration,  
(iv) improvement of the therapeutic index and therefore reducing the toxicity, (v) improvement of the 
compliance of the dose intake by the patients, (vi) possibility of use of non-invasive routes of 
administration for drugs having unsuitable biopharmaceutical and/or pharmaockinetics properties for 
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administrations alternative to parenteral route and then to favor the pharmaco-economical aspects of 
certain drugs administrable only by injectable administrations (vii) reduction of the general exposition 
of the host to the active agent. Indeed, a lot of active compounds, although they are very potent,  
are not able to reach an effective blood concentration, due to absorption, distribution, half-life or 
stability problems. 
Two classes of raw materials, lipids and polymers, can be used to build these colloidal particles 
using nano/microtechnologies based techniques. Besides the choice of the nature of the raw materials, 
the synthesis protocol is also a key factor to be taken into account since this can drastically modify the 
particle size, surface charge and the physicochemical characteristics (hydrophilic/hydrophobic).  
Many biocompatible raw materials have been suggested for this purpose which may include 
phospholipids, medium- and long-chain-triglyceride lipid-based systems, polylactide and copolymers, 
polysaccharides such as hyaluronic acids, chitosan, alginate etc. As mentioned above, these particles 
can be prepared by various methods using preformed polymers or polymerizing a monomer during the 
preparation process. 
The Trojan microparticles, due to their architecture, can improve the mucosal absorption of drugs 
either by means of prolonged retention and preferred transport at mucosal site or by protection of 
carrier substance from degradation. The optimizing of the biopharmaceutical properties of drugs by 
means of particulate carriers is a real challenge leading to innovation. 
Puerarin is an isoflavone isolated from a Chinese herbal medicine, Radix Puerariae Lobatae, and 
has been reported to have a comprehensive pharmacological action in the treatment of diabetes and 
cardiovascular diseases. Puerarin is a water-soluble drug which has a short half-life in the body. One 
way to increase its therapeutic efficacy is to prepare nanoparticles of this active compound and then to 
microencapsulate using a supercritical CO2 process or to use a co-precipitation process using 
biodegradable polymers to produce a sustained release effect. In vitro, Chen et al. [10] found that the 
puerarin nanoparticles were released very quickly through the dialysis bag, and the drug dissolved 
completely in 6 h. After microencapsulation of puerarin by poly(L-lactide) (PLLA), the puerarin PLLA 
microparticles showed a burst of release, and about 60.2% of the puerarin was released in the first 4 h; 
this result demonstrated that this puerarin fraction can be easily removed, which was similar to the 
results of the encapsulation efficiency measurements. After that, the microparticles released the drug in 
a sustained process, about 89.6% of the drug was released within 24 h and was finally completely 
released in 36 h. After incubation in PBS (pH 6.8) for 24 and 48 h, it was seen that after  
24 hours the surface became cleaner and some micropores were observed due to the removal of 
puerarin nanoparticles while after 48 h more micropores were generated by the continuous removal of 
puerarin nanoparticles. 
Thote and Gupta also used supercritical carbon dioxide to microencapsulate nanoparticles of 
dexamethasone phosphate, a hydrophilic drug, in order to sustain its release [8]. In vitro drug release 
of dexamethasone phosphate nanoparticles encapsulated in PLGA microparticles was compared to the 
unprocessed drug particles as provided by the supplier also encapsulated in PLGA microspheres. The 
in vitro drug release of the unprocessed drug particles (but microencapsulated) showed an initial burst 
release of about 5% at time zero, and the entire drug was released within 24 hours. This kinetic release 
is not advisable for sustained drug release. On the other hand, the in vitro drug release of the 
nanoparticles (also microencapsulated) obtained using supercritical antisolvent technique with enhanced 
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mass transfer (SAS-EM) showed continuous release for 700 hours. The release profile showed almost 
no burst release, however ~15% was released in the first 60 hours followed by a stationary state of 
about 200 hours, during which only 22% of the encapsulated drug was released. This was followed 
with continuous increase in the drug release rate up to 500 hours, during which about 75% of the drug 
was released followed by continued release of the drug over time. From the sustained drug release 
profile, the authors clearly inferred that the drug was well dispersed in the polymer matrix, which 
allowed gradual release of the drug with polymer degradation, as opposed to initial burst release 
observed in the case where the w/o/o/o phase separation technique was used for encapsulation of 
dexamethasone phosphate. As the complete process was anhydrous, Thote and Gupta suggested that 
similar sustained release formulations could also be produced for other hydrophilic drugs. 
In order to decrease the initial burst release of low molecular weight drugs from formulations 
including drug-loaded micro- and nanoparticles, Hasan et al. [48] prepared composite microparticles 
by using w/o/w emulsion process. They encapsulated polymeric nanoparticles into polymeric 
microparticles by using non-water soluble polymers and appropriate organic solvents. They compared 
the release kinetics with nanoparticles and classical microparticles prepared by the same method.  
Poly-ε-caprolactone (PCL) dissolved in methylene chloride was used to make nanoparticles, whereas 
ethylcellulose and Eudragit RS dissolved in ethyl acetate, a non-solvent of poly-ε-caprolactone, were 
used for the preparation of microparticles. Ibuprofen and triptorelin acetate were chosen as lipophilic 
and hydrophilic model drugs, respectively. High entrapment efficiencies were obtained with ibuprofen 
whereas lower amounts of triptorelin acetate were encapsulated, mainly with formulations prepared 
with poly-ε-caprolactone and Eudragit RS used alone or blended with ethylcellulose. The authors 
showed that the burst was significantly lower with composite microparticles and may be explained by 
the slower diffusion of the drugs through the double polymeric wall formed by the nanoparticle matrix 
followed by another diffusion step through the microparticle polymeric wall. 
The solutions of optimized drug releases given by the technology of Trojan microparticles can be 
extended to the ocular route. Gómez-Gaete et al. [7] combined the therapeutic potential of nanoparticles 
systems with the ease of manipulation of microparticles by developing Trojan particles. The aim of 
their new delivery vehicle was to be used for intravitreal administration of dexamethasone (DXM). 
Indeed, the presence of crystalline drug along with the nanoparticles considerably reduces its ability to 
load the polymeric matrix. However, Gómez et al. demonstrated that 1.3 mg DXM (=1.44 mg 
dexamethasone acetate (DXA)) could be encapsulated into 100 mg nanoparticles which was about  
6 fold more than what could be obtained by using dexamethasone. Initially, they optimized dexamethasone 
acetate (DXA) encapsulation into biodegradable poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles, 
then Trojan particles were formulated by spray drying 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine 
(DPPC), hyaluronic acid (HA) and different concentrations of nanoparticle suspensions. The effects of 
nanoparticles concentration on the physical characteristics of Trojan particles as well as the effect of 
the spray drying process on nanoparticles size were investigated. Finally, DXA in vitro release from 
nanoparticles and Trojan particles was evaluated under sink condition. Although a burst effect can be 
observed with both systems, the extent of the burst was lower for Trojan particles. SEM and confocal 
microscopy confirmed that most of Trojan particles were spherical, hollow and possessed an irregular 
surface due to the presence of nanoparticles. The authors observed that neither Trojan particle tap 
density nor size distribution was significantly modified as a function of nanoparticles concentration. 
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They mean size distribution of nanoparticles was also found to increase significantly after spray 
drying. Finally, based on in vitro release of DXA they showed that the excipient matrix provided 
protection to encapsulated nanoparticles by slowing down drug release. Gómez et al. concluded that 
even if the active principle was released rather quickly as compared with other implants, the in situ 
release of drug loaded nanoparticles should favor their internalization within retinal pigment epithelial 
cells and might therefore increase the drug efficacy for treating retinal affections. 
New transmucosal administration routes, like the pulmonary, could also be exploited for systemic 
absorption of drugs. Edwards et al. [51] were the first to show that very light particles (ρ <~ 0.4 g/cm3) 
with d > 5 μm can be deposited in the lungs. As a consequence of their large size and low mass 
density, porous particles can aerosolize from a DPI more efficiently than smaller nonporous particles, 
resulting in higher respirable fractions of inhaled therapeutics. Also by virtue of their size, large 
particles can avoid phagocytic clearance from the lungs until the particles have delivered their 
therapeutic dose; this attribute can be particularly useful for controlled-release inhalation therapies. To 
optimize physiologically the kinetic release of the drug incorporated into these Large Porous Particles 
(LPPs) and to allow producing them easily, Tsapis et al. [22] combined the drug release and delivery 
potential of nanoparticle systems with the ease of flow, processing, and aerosolization potential of 
Large Porous Particle (LPP) systems by spray drying solutions of polymeric and nonpolymeric NPs 
into extremely thin-walled macroscale structures. These hybrid LPPs exhibited better flow and 
aerosolization properties than the NPs; yet, unlike the LPPs, which dissolved in physiological 
conditions to produce molecular constituents, the hybrid LPPs dissolved to produce NPs, with the drug 
release and delivery advantages associated with NP delivery systems. Formation of the large porous 
NP (LPNP) aggregates occurred via a spray-drying process that ensured that the drying time of the 
sprayed droplet was sufficiently shorter than the characteristic time for redistribution of NPs by 
diffusion within the drying droplet, implying a local Peclet number much greater than unity. 
Additional control over LPNPs physical characteristics were achieved by adding other components to 
the spray-dried solutions, including sugars, lipids, polymers, and proteins. The ability to produce 
LPNPs appeared to be largely independent of molecular component type as well as the size or 
chemical nature of the NPs. Hadinoto et al. [42,52] developed similar drug delivery systems based on 
large hollow nanoparticulate aggregates as therapeutic carrier particles in dry powder inhaler delivery 
of nanoparticulate drugs. The large hollow carrier particles were manufactured by spray drying of 
nanoparticulate suspensions of biocompatible acrylic polymer with loaded drugs. The size and 
concentration of the nanoparticles, as well as the phospholipids inclusion, have been known to 
influence the resulting morphology (i.e., size and degree of hollowness) of the spray-dried carrier 
particles. The effects of the resulting morphology of the carrier particles on the drug release rate were 
therefore investigated by varying the above three variables. To study these different factors, the 
authors used aspirin and salbutamol sulfate since these two model drugs have a varying degree of 
solubility in water. The results indicated that the drug release rate is mostly governed by the degree of 
hollowness of the carrier particles, and also to a lesser extent by the nanoparticles size, where variation 
in the drug loading capacity of nanoparticles was observed for different particle size. 
Design of appropriate inhaled carriers with adequate aerodynamic properties, drug release, 
biodegradation and evasion of macrophage uptake is a major challenge for controlled release pulmonary 
drug delivery [53,54]. In order to reach this aim, Al-Qadi et al. [55] and El-Sherbiny et al. [56] 
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prepared hybrid PEG graft copolymerized onto N-phthaloyl chitosan and chitosan/hyaluronic acid 
nanoparticles, by ionotropic gelation, and microencapsulated them respectively in sodium alginate and 
mannitol microspheres, resulting in a dry powder that showed adequate aerodynamic properties for 
deep pulmonary deposition. Following the encapsulation process, structural analysis of the dry powder 
was analyzed by confocal laser scanning microscopy, which elucidated that the nanoparticles were 
homogeneously distributed within the mannitol microsphere. The evidence that nanoparticles were 
completely encapsulated within the carrier by means of the spray drying process was achieved by 
application of the sensitive surface analysis techniques, X-ray photoelectron spectroscopy and in 
combination with time-of-flight secondary ion mass spectroscopy. These outcomes confirmed the success 
of nanoparticles microencapsulation by spray drying and the authors concluded that the developed 
delivery system holds great potential for lung delivery of macromolecules. Grenha et al. [43,57] 
concluded similarly by studying chitosan nanoparticle-loaded mannitol microspheres. The mannitol 
microspheres contained chitosan/tripolyphosphate nanoparticles and were also prepared by spray-drying. 
These microspheres were proposed as valuable candidates to transport therapeutic protein-loaded 
nanoparticles to the lungs owing to their favorable aerodynamic properties. Similar formulations were 
developed by other researchers in order to open the way for new drug-targeting strategies using 
nanoparticles for proteins [58] and pulmonary delivery of drugs and diagnostics. Indeed, some of  
them [59] developed a platform for aerosol delivery of nanoparticles. In this case, lactose was used as 
the excipient and spray-dried with two different types of nanoparticles: gelatin and polybutylcyanoacrylate 
nanoparticles. The results of these studies showed that some carrier particles were hollow while others 
had a continuous matrix. Gelatin nanoparticles were incorporated throughout the matrix and 
sometimes accumulated at one end of the lactose. Polycyanoacrylate nanoparticles mostly clustered in 
different spots within the lactose carriers. The mean sizes of both nanoparticle types were characterized 
at two different times: one just before they were spray-dried and other after they were redissolved from 
the spray-dried powders. Both nanoparticle types remained in the nano-range size after spray-drying. 
The mean nanoparticle sizes were increased by approximately 30% after spray-drying, though this 
increase was statistically significant only for the gelatin nanoparticles. Dispersion of the powder with 
an in-house passive dry powder inhaler and subsequent cascade impaction measurements showed that 
incorporation of the nanoparticles did not affect the fine particle fraction (FPF) or mass median 
aerodynamic diameter (MMAD) of the powders. FPF was approximately 40% while MMAD was  
3.0 ± 0.2 μm, indicating these formulations yielded aerosols of a suitable particle size for efficient lung 
delivery of nanoparticles. As for the other delivery systems intended for this administration route, the 
researchers demonstrated that nanoparticles can be delivered to the lungs via carrier particles that 
dissolve after coming in contact with the aqueous environment of the lung epithelium. 
Besides the specific uses of Trojan microspheres for pulmonary delivery, the particles have also 
found applications for oral administration, to reach desirable sustained release profiles.  
El-Sherbiny et al. [60] developed a series of nano/micro hydrogel matrices for oral delivery of 
silymarin. This drug was chosen as a model of hydrophobic natural therapeutics. Constituted of sodium 
alginate-based pH responsive hydrogel microspheres encapsulating poly(D,L-lactic-co-glycolic acid) 
(PLGA) nanoparticles (NPs), this new design of particles allowed enhancing the dissolution and oral 
bioavailability of this model drug via formulation in polymeric matrices. From these studies, the 
authors showed that alginate-based hydrogel microparticles incorporating silymarin-loaded PLGA NPs 
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are pH-sensitive. Also, the obtained data revealed a considerable effect of the alginate content and the 
drying method onto the characteristics of the prepared alginate-PLGA particles. 
In the field of gene delivery by oral route, Bhavsar et al. [49,61] investigated the development and 
the evaluation of a novel nanoparticles-in-microsphere oral system (NiMOS) for gene delivery and 
transfection in specific regions of the gastrointestinal (GI) tract. To achieve this, plasmid DNA, 
encoding either for β-galactosidase (CMV-βgal) or enhanced green fluorescent protein (EFGP-N1), 
was encapsulated in type B gelatin nanoparticles. NiMOS were prepared by further protecting the 
DNA-loaded nanoparticles in a poly(epsilon-caprolactone) (PCL) matrix to form microspheres of less 
than 5.0 μm in diameter. In order to evaluate the biodistribution following oral administration, 
radiolabeled (111In-labeled) gelatin nanoparticles and NiMOS were administered orally to fasted 
Wistar rats. The results of biodistribution studies showed that, while gelatin nanoparticles traversed 
through the GI tract rather quickly with more than 85% of the administered dose per gram localizing in 
the large intestine within the first hour, NiMOS resided in the stomach and small intestine for 
relatively longer duration. Following oral administration of CMV-βgal or EFGP-N1 plasmid DNA at 
100 μg dose in the control and test formulations, the qualitative results presented in this study provide 
the proof-of-concept for the transfection capability of NiMOS upon oral administration. After 5 days 
post-administration, the authors observed transgene expression in the small and large intestine of rats. 
Based on these preliminary results, NiMOS showed significant potential as novel gene delivery vehicle 
for therapeutic and vaccination purposes. 
Several other peculiar applications have been investigated for the Trojan microparticles. These ones 
comprise the possibility to incorporate iron oxide. In this context, superparamagnetic iron oxide 
nanoparticles embedded chitosan microspheres were developed for magnetic resonance (MR)-traceable 
embolotherapy with high resolution and sensitivity through magnetic resonance imaging (MRI) [62]. 
Superparamagnetic iron oxide nanoparticles loaded chitosan microspheres were prepared by emulsion 
and cross-linking technique and 100–200 μm sized spherical microsparticles were obtained. Within  
30 days, about 60% of the incorporated superparamagnetic iron oxide nanoparticles were released 
from low cross-linked microspheres, whereas only about 40% of superparamagnetic iron oxide 
nanoparticles were released from highly cross-linked microspheres. Highly cross-linked microspheres 
were more efficient for lower degree of swelling leading to secure entrapment of superparamagnetic 
iron oxide nanoparticles in matrix. 
Drug-loaded microspheres using the proof-of-concept of Trojan particles, a kind of target-orientation 
drug, were also investigated by several researchers. Drug delivery systems constituted of a magnetic 
polymeric carrier, composed of biodegradable poly(D,L-lactide) microspheres, maghemite nanoparticles 
and anti-cancer drug (paclitaxel) was successfully prepared in dichloromethane using highspeed 
homogenization [63]. Maghemite nanoparticles were well dispersed in poly(D,L-lactide) matrix. The 
carrier was magnetically responsive and release of loaded paclitaxel was enhanced by applying an 
oscillating magnetic field. The thermal energy generated by maghemite nanoparticles due to magnetic 
hysteresis loss was very low and had a negligible effect in influencing the release behavior. The 
authors showed that alternating movement of the nanoparticles, stimulated by magnetic force, resulting 
in deterioration of the mechanical properties of polymer matrix was likely to be the main reason for the 
enhancement in drug release. Similar systems containing paclitaxel or interferon alpha-2b were 
respectively formulated by Cui et al. [64] and Zhou et al. [65]. 
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In an anecdotic way, one can also mention the use of hybrid particles for the enzyme 
immobilization. Sadjadi et al. [66] investigated the assembly of the silver nanoparticles on the surface 
of the amine-functionalized zeolite microspheres or formation of zeolitesilver nanoparticle “core-shell” 
structure and thereafter, using this nanosystem in immobilization of fungal protease. The assembly  
of silver nanoparticles on zeolite surface occurs through the amine groups present in  
3-aminopropyltrimethoxysilane. The fungal proteases bound to the massive “core-shell” structures can 
be easily separated from the reaction medium by mild centrifugation and exhibited excellent reuse 
characteristics. The biocatalytic activity of fungal protease in the bioconjugate was marginally 
enhanced relative to the free enzyme in solution. 
Using the technology of the encapsulation of nanoparticles into microspheres, Lee et al. [67] 
reported the antibacterial properties of magnetically directed microparticles containing Ag nanoparticle 
loaded multilayers. Original development of Trojan microspheres was realized in tissue-regeneration 
matrix and drug delivery systems. Park et al. [68] applied these biomaterials as novel cell supporting 
matrix for stem cell delivery. They devised a novel method for the fabrication of nanostructured 3D 
scaffolds. The growth factor loaded heparin/poly(L-lysine) nanoparticles were physically attached on 
the positively charged surface of PLGA microspheres precoated with low molecular weight 
poly(ethyleneimmine) via a layer-by-layer system. Growth factor loaded heparin/poly(L-lysine) 
nanoparticles, which were simply produced as polyion complex micelles with diameters of 50–150 nm, 
were fabricated in the first step. Microsphere matrix (size, 20~80 nm) containing TGF-β 3 showed a 
significantly higher number of specific lacunae phenotypes at the end of the 4 week study in vitro 
culture of mesenchymal stem cells. Thus, the researchers concluded that growth factor delivery of 
polylactide-co-glycolide microsphere can be used to engineer synthetic extracellular matrix. This 
polymeric microsphere matrix containing TGF-β 3 showed promise as coatings for implantable 
biomedical devices to improve biocompatibility and ensure in vivo performance. 
4. Conclusion 
As demonstrated above, the hybrid particles present a lot of pharmaceutical interests since these 
technologies are able to envisage the desirable pharmacokinetic for a drug. They should contribute 
towards improvement of targeting properties of a drug; decrease the dosage amount to be administered 
to a patient and to improve the comfort of patients by minimizing side effects. From a toxicological 
point of view, since the greater surface area per mass compared with larger-sized particles of the same 
chemistry renders nanosized particles more active biologically, these Trojan particles have to be 
evaluated toxicologically as microspheres and nanoparticles. As nanoparticles, their toxicological 
evaluation includes a potential for inflammatory and pro-oxidant, but also antioxidant activity, which 
can explain early findings showing mixed results in terms of toxicity of nanosized particles [69]. 
Evidence of mitochondrial distribution and oxidative stress response after nanosized particle 
endocytosis and their possible interactions with subcellular structures have also to be studied. 
Additional considerations for assessing safety of engineered nanosized particles include also careful 
selections of appropriate and relevant doses/concentrations, the likelihood of increased effects in a 
compromised organism, and also the benefits of possible desirable effects. 
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